BRPI0607874A2 - análises de microarranjo e microdissecção a laser de tumores de mama revelam genes relacionados com receptor de estrogênio e vias - Google Patents

análises de microarranjo e microdissecção a laser de tumores de mama revelam genes relacionados com receptor de estrogênio e vias

Info

Publication number
BRPI0607874A2
BRPI0607874A2 BRPI0607874-5A BRPI0607874A BRPI0607874A2 BR PI0607874 A2 BRPI0607874 A2 BR PI0607874A2 BR PI0607874 A BRPI0607874 A BR PI0607874A BR PI0607874 A2 BRPI0607874 A2 BR PI0607874A2
Authority
BR
Brazil
Prior art keywords
genes
dataset
pathways
estrogen receptor
tumors
Prior art date
Application number
BRPI0607874-5A
Other languages
English (en)
Inventor
Jack Yu
Yuqiu Jiang
Fei Yang
Yixin Wang
Original Assignee
Veridex Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Veridex Llc filed Critical Veridex Llc
Publication of BRPI0607874A2 publication Critical patent/BRPI0607874A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

ANáLISES DE MICROARRANJO E MICRODISSECçãO A LASER DE TUMORES DE MAMA REVELAM GENES RELACIONADOS COM RECEPTOR DE ESTROGêNIO E VIAS. Cerca de 70% a 80% de cânceres de mama expressam receptor de estrogênio <244> (ER<244>), e os estrogênios exercem funções importantes no desenvolvimento e crescimento de tumores dependentes de hormónio. Juntamente com metástase linfonodal, o tamanho e grau histológico do tumor, o estado ER é considerado um dos fatores prognósticos em câncer de mama, e um indicador para tratamento hormonal. 147 genes e 112 genes com valor-P significativo e que possuem expressão diferencial significativa entre tumores ER+ e ER- foram identificados a partir de conjunto de dados de LCM e conjunto de dados de tecido volumoso, respectivamente. 61 genes foram considerados comuns em ambos os conjuntos de dados, enquanto 85 genes eram exclusivos ao conjunto de dados de LOM e 51 genes estavam presentes apenas no conjunto de dados de tumor volumoso. A análise de vias com 85 genes utilizando Gene Ontology sugeriu que os genes envolvidos em endocitose, geração de ceramida, cascata Ras/ERK/Ark, e via JATSTAT pode exercer funções relacionadas com ER. A definição de perfil de gene com células de tumor capturadas por LCM proporciona uma abordagem única para caracterizar e estudar as células tumorais epiteliais e para obter um conhecimento sobre as vias de sinalização associadas com ER.
BRPI0607874-5A 2005-04-04 2006-04-03 análises de microarranjo e microdissecção a laser de tumores de mama revelam genes relacionados com receptor de estrogênio e vias BRPI0607874A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66800505P 2005-04-04 2005-04-04
PCT/US2006/013004 WO2006108135A2 (en) 2005-04-04 2006-04-03 Laser microdissection and microarray analysis of breast tumors reveal estrogen receptor related genes and pathways

Publications (1)

Publication Number Publication Date
BRPI0607874A2 true BRPI0607874A2 (pt) 2009-10-20

Family

ID=37074106

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0607874-5A BRPI0607874A2 (pt) 2005-04-04 2006-04-03 análises de microarranjo e microdissecção a laser de tumores de mama revelam genes relacionados com receptor de estrogênio e vias

Country Status (8)

Country Link
US (1) US20080305959A1 (pt)
EP (1) EP1874960A2 (pt)
JP (1) JP2008538284A (pt)
CN (1) CN101965190A (pt)
BR (1) BRPI0607874A2 (pt)
CA (1) CA2603898A1 (pt)
MX (1) MX2007012395A (pt)
WO (1) WO2006108135A2 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010088498A1 (en) * 2009-01-30 2010-08-05 Bayer Healthcare Llc Methods for treating estrogen receptor positive cancer by x-box binding protein 1 inhibition
DE102012207240A1 (de) * 2012-05-02 2013-11-07 Leica Microsystems Cms Gmbh Laser-Mikrodissektionsgerät und -verfahren
CN107574243B (zh) * 2016-06-30 2021-06-29 博奥生物集团有限公司 分子标志物、内参基因及其应用、检测试剂盒以及检测模型的构建方法
CN110144403B (zh) * 2017-02-24 2022-05-10 北京致成生物医学科技有限公司 一种乳腺癌治病基因rbm12b的新突变snp位点及其应用
US20180251849A1 (en) * 2017-03-03 2018-09-06 General Electric Company Method for identifying expression distinguishers in biological samples
KR102071491B1 (ko) * 2017-11-10 2020-01-30 주식회사 디시젠 차세대 염기서열분석을 이용한 기계학습 기반 유방암 예후 예측 방법 및 예측 시스템

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5700637A (en) * 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
GB8822228D0 (en) * 1988-09-21 1988-10-26 Southern E M Support-bound oligonucleotides
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5242974A (en) * 1991-11-22 1993-09-07 Affymax Technologies N.V. Polymer reversal on solid surfaces
US5527681A (en) * 1989-06-07 1996-06-18 Affymax Technologies N.V. Immobilized molecular synthesis of systematically substituted compounds
US5384261A (en) * 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
US5412087A (en) * 1992-04-24 1995-05-02 Affymax Technologies N.V. Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces
US5554501A (en) * 1992-10-29 1996-09-10 Beckman Instruments, Inc. Biopolymer synthesis using surface activated biaxially oriented polypropylene
US5472672A (en) * 1993-10-22 1995-12-05 The Board Of Trustees Of The Leland Stanford Junior University Apparatus and method for polymer synthesis using arrays
US5429807A (en) * 1993-10-28 1995-07-04 Beckman Instruments, Inc. Method and apparatus for creating biopolymer arrays on a solid support surface
US5571639A (en) * 1994-05-24 1996-11-05 Affymax Technologies N.V. Computer-aided engineering system for design of sequence arrays and lithographic masks
US5556752A (en) * 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US5599695A (en) * 1995-02-27 1997-02-04 Affymetrix, Inc. Printing molecular library arrays using deprotection agents solely in the vapor phase
US5624711A (en) * 1995-04-27 1997-04-29 Affymax Technologies, N.V. Derivatization of solid supports and methods for oligomer synthesis
US5545531A (en) * 1995-06-07 1996-08-13 Affymax Technologies N.V. Methods for making a device for concurrently processing multiple biological chip assays
US5658734A (en) * 1995-10-17 1997-08-19 International Business Machines Corporation Process for synthesizing chemical compounds
US6136182A (en) * 1996-06-07 2000-10-24 Immunivest Corporation Magnetic devices and sample chambers for examination and manipulation of cells
US6218114B1 (en) * 1998-03-27 2001-04-17 Academia Sinica Methods for detecting differentially expressed genes
US6004755A (en) * 1998-04-07 1999-12-21 Incyte Pharmaceuticals, Inc. Quantitative microarray hybridizaton assays
US6218122B1 (en) * 1998-06-19 2001-04-17 Rosetta Inpharmatics, Inc. Methods of monitoring disease states and therapies using gene expression profiles
US6271002B1 (en) * 1999-10-04 2001-08-07 Rosetta Inpharmatics, Inc. RNA amplification method
US20050260572A1 (en) * 2001-03-14 2005-11-24 Kikuya Kato Method of predicting cancer
WO2002092854A2 (en) * 2001-05-16 2002-11-21 Novartis Ag Genes expressed in breast cancer as prognostic and therapeutic targets
US7306910B2 (en) * 2003-04-24 2007-12-11 Veridex, Llc Breast cancer prognostics

Also Published As

Publication number Publication date
WO2006108135A8 (en) 2007-11-15
CA2603898A1 (en) 2006-10-12
WO2006108135A9 (en) 2009-10-15
WO2006108135A2 (en) 2006-10-12
CN101965190A (zh) 2011-02-02
EP1874960A2 (en) 2008-01-09
MX2007012395A (es) 2008-04-14
JP2008538284A (ja) 2008-10-23
US20080305959A1 (en) 2008-12-11

Similar Documents

Publication Publication Date Title
Song et al. Global histone modification pattern associated with recurrence and disease‐free survival in non‐small cell lung cancer patients
Ma et al. m6A methyltransferase METTL3 promotes the progression of prostate cancer via m6A-modified LEF1
Pradhan et al. Epigenetic silencing of genes enhanced by collective role of reactive oxygen species and MAPK signaling downstream ERK/Snail axis: Ectopic application of hydrogen peroxide repress CDH1 gene by enhanced DNA methyltransferase activity in human breast cancer
Tang et al. A CD90+ tumor-initiating cell population with an aggressive signature and metastatic capacity in esophageal cancer
Noh et al. Acetylation status of P53 and the expression of DBC1, SIRT1, and androgen receptor are associated with survival in clear cell renal cell carcinoma patients
Mukherjee et al. Modulation of SOX2 expression delineates an end-point for paclitaxel-effectiveness in breast cancer stem cells
Cho et al. Aberrant promoter hypermethylation and genomic hypomethylation in tumor, adjacent normal tissues and blood from breast cancer patients
Costa et al. The epigenetics of testicular germ cell tumors: Looking for novel disease biomarkers
Smits et al. Genetic and epigenetic alterations in the von hippel-lindau gene: the influence on renal cancer prognosis
Hu et al. Morphologic spectrum of neuroendocrine tumors of the prostate: an updated review
Choi et al. Expression of Bmi-1 protein in tumor tissues is associated with favorable prognosis in breast cancer patients
González-Rodilla et al. The E-Cadherin expression vs. tumor cell proliferation paradox in endometrial cancer
Yang et al. Detection of alpha-methylacyl-coenzyme A racemase in postradiation prostatic adenocarcinoma
Na et al. CTNNB1 mutations in ovarian microcystic stromal tumors: identification of a novel deletion mutation and the use of pyrosequencing to identify reported point mutation
Lawrenson et al. Identification of novel candidate biomarkers of epithelial ovarian cancer by profiling the secretomes of three‐dimensional genetic models of ovarian carcinogenesis
Shafiei et al. Increased expression of DCLK1, a novel putative CSC maker, is associated with tumor aggressiveness and worse disease-specific survival in patients with bladder carcinomas
Liu et al. TMEM196 acts as a novel functional tumour suppressor inactivated by DNA methylation and is a potential prognostic biomarker in lung cancer
Beilmann-Lehtonen et al. High tissue TLR5 expression predicts better outcomes in colorectal cancer patients
Saranya et al. Expression of sex hormones in oral squamous cell carcinoma: a systematic review on immunohistochemical studies
BRPI0607874A2 (pt) análises de microarranjo e microdissecção a laser de tumores de mama revelam genes relacionados com receptor de estrogênio e vias
Lam et al. Clinicopathological roles of alterations of tumor suppressor gene p16 in papillary thyroid carcinoma
Chen et al. Expression and clinical significance of androgen receptor in bladder cancer: A meta‑analysis
Kim et al. Mutually exclusive antiproliferative effect of cell line‐specific HOX inhibition in epithelial ovarian cancer cell lines: SKOV‐3 vs RMUG‐S
Kaushal et al. Oncogenic potential of truncated-Gli3 via the Gsk3β/Gli3/AR-V7 axis in castration-resistant prostate cancer
Reis-Filho Low-estrogen receptor-positive breast cancer: the impact of tissue sampling, choice of antibody, and molecular subtyping

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]